Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

· Issued by Arcutis Biotherapeutics, Inc.

On 6ix: 6ix.com/news/arcutis-announces-positive-topline-results-from-second-atopic-dermatitis-pivotal

Watch Arcutis Biotherapeutics' latest callArcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Arcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings Call
Arcutis Biotherapeutics' next earnings callArcutis Biotherapeutics (NASDAQ:ARQT) Q3 2026 Earnings Call · Nov 4, 2026 at 4:30 PM ESTRegister
  • Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from the INTEGUMENT-1 trial released in November
  • For the primary endpoint, 28.9% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success compared to 12.0% of individuals treated with vehicle (P

Arcutis Biotherapeutics, Inc. on 6ix

Story so far

Earlier from Arcutis Biotherapeutics

Later from Arcutis Biotherapeutics

All Arcutis Biotherapeutics news releases